JUVENILE MYASTHENIA GRAVIS

被引：84

作者：

Chiang, Laura M. ^{[1
]}

Darras, Basil T. ^{[1
]}

Kang, Peter B. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Neurol, Boston, MA 02115 USA

来源：

MUSCLE & NERVE | 2009年 / 39卷 / 04期

关键词：

juvenile myasthenia gravis; neuromuscular junction; pediatric autoimmune disease; myasthenia; acetylcholine; ACETYLCHOLINE-RECEPTOR ANTIBODIES; TERM FOLLOW-UP; MYCOPHENOLATE-MOFETIL; DOUBLE-BLIND; CHILDREN; CHILDHOOD; ONSET; THERAPY; THYMECTOMY; DIAGNOSIS;

D O I：

10.1002/mus.21195

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Juvenile myasthenia gravis shares a similar pathophysiologic origin with adult myasthenia gravis, but there are important differences, mostly relating to epidemiology, presentation, and therapeutic decision making. Gender ratios and the proportion of seropositive patients differ in the pre- and postpubertal age groups. The diagnostic evaluation is similar to that in adults, although special techniques are sometimes necessary to perform single-fiber electromyography in younger patients. Therapeutic decisions in affected children and adolescents are complicated by the greater long-term consequences of using steroids, and thus other interventions, such as intravenous immunoglobulin (IVIg) and plasmapheresis, may play a greater therapeutic role in this population than in adults. Steroid-sparing agents may contribute to the management of refractory cases, but they should be used with caution due to the risk of malignancy.

引用

页码：423 / 431

页数：9

共 45 条

[1] DRUGS THAT MAY EXACERBATE MYASTHENIA-GRAVIS [J].

ADAMS, SL ;

MATHEWS, J ;

GRAMMER, LC .

ANNALS OF EMERGENCY MEDICINE, 1984, 13 (07) :532-538

[2]

ANDREWS P, 2003, NEUROMUSCULAR DISORD

[3] RACE, SEX, AND PUBERTY INFLUENCE ONSET, SEVERITY, AND OUTCOME IN JUVENILE MYASTHENIA-GRAVIS [J].

ANDREWS, PI ;

MASSEY, JM ;

HOWARD, JF ;

SANDERS, DB .

NEUROLOGY, 1994, 44 (07) :1208-1214

[4] Myasthenia gravis in children: a longitudinal study [J].

Ashraf, V. V. ;

Taly, A. B. ;

Veerendrakumar, M. ;

Rao, S. .

ACTA NEUROLOGICA SCANDINAVICA, 2006, 114 (02) :119-123

[5] EARLY-ONSET MYASTHENIA-GRAVIS - CLINICAL CHARACTERISTICS AND RESPONSE TO THERAPY [J].

BATOCCHI, AP ;

EVOLI, A ;

PALMISANI, MT ;

LOMONACO, M ;

BARTOCCIONI, M ;

TONALI, P .

EUROPEAN JOURNAL OF PEDIATRICS, 1990, 150 (01) :66-68

[6] A CRITICAL-REVIEW OF IMMUNOSUPPRESSIVE THERAPY [J].

BRIGGS, JD .

IMMUNOLOGY LETTERS, 1991, 29 (1-2) :89-94

[7] Mycophenolate mofetil treatment of myasthenia gravis [J].

Cahoon, WD ;

Kockler, DR .

ANNALS OF PHARMACOTHERAPY, 2006, 40 (02) :295-298

[8] Mycophenolate mofetil: A new immunosuppressive approach successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection [J].

Caponnetto, C ;

Rossi, E ;

Primavera, A .

EUROPEAN NEUROLOGY, 2001, 46 (01) :53-54

[9] Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases [J].

Chaudhry, V ;

Cornblath, DR ;

Griffin, JW ;

O'Brien, R ;

Drachman, DB .

NEUROLOGY, 2001, 56 (01) :94-96

[10] MYASTHENIA-GRAVIS AND HLA ANTIGENS IN AMERICAN BLACKS AND OTHER RACES [J].

CHRISTIANSEN, FT ;

POLLACK, MS ;

GARLEPP, MJ ;

DAWKINS, RL .

JOURNAL OF NEUROIMMUNOLOGY, 1984, 7 (2-3) :121-129

← 1 2 3 4 5 →